1.
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
by Liang, Wenhua
The lancet oncology, 2020-03, Vol.21 (3), p.335-337
2.
Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and document...
by White, Jane V
Journal of the Academy of Nutrition and Dietetics, 2012-05, Vol.112 (5), p.730
3.
Thyroid cancer
by Cabanillas, Maria E, Dr
The Lancet (British edition), 2016, Vol.388 (10061), p.2783-2795
4.
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
by Cross, Marita
Annals of the rheumatic diseases, 2014-07, Vol.73 (7), p.1316-1322
5.
An inflammatory cytokine signature predicts COVID-19 severity and survival
by Del Valle, Diane Marie
Nature medicine, 2020-10, Vol.26 (10), p.1636-1643
6.
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
by Thevarajan, Irani
Nature medicine, 2020-04-01, Vol.26 (4), p.453-455
7.
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
by Paramsothy, Sudarshan, MD
The Lancet (British edition), 2017, Vol.389 (10075), p.1218-1228
8.
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
by Tian, Jianbo
The lancet oncology, 2020-07, Vol.21 (7), p.893-903
9.
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
by Smolen, Josef S Josef S
Annals of the rheumatic diseases, 2015-05-12, Vol.75 (1), p.3-15
10.
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
by Wu, Joseph T
Nature medicine, 2020-04, Vol.26 (4), p.506-510
11.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-infer...
by Jørgensen, Kristin K, PhD
The Lancet (British edition), 2017, Vol.389 (10086), p.2304-2316
12.
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study
by Liu, Sean T H
Nature medicine, 2020-11, Vol.26 (11), p.1708-1713
13.
The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study
by Cross, Marita
Annals of the rheumatic diseases, 2014-07, Vol.73 (7), p.1323-1330
14.
Real-time tracking of self-reported symptoms to predict potential COVID-19
by Menni, Cristina
Nature medicine, 2020-07, Vol.26 (7), p.1037-1040
15.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging p...
by Thaçi, Diamant, Prof
The Lancet (British edition), 2016, Vol.387 (10013), p.40-52
16.
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
by Yang, Kunyu
The lancet oncology, 2020-07, Vol.21 (7), p.904-913
17.
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
by Wilk, Aaron J
Nature medicine, 2020-07, Vol.26 (7), p.1070-1076
18.
Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial
by The AVERT Trial Collaboration group
The Lancet (British edition), 2015, Vol.386 (9988), p.46-55
19.
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
by Abdulqawi, Rayid, PhD
The Lancet (British edition), 2015, Vol.385 (9974), p.1198-1205
20.
A dynamic COVID-19 immune signature includes associations with poor prognosis
by Laing, Adam G
Nature medicine, 2020-10, Vol.26 (10), p.1623-1635
